Tasquinimod is an oral S100A9 inhibitor being evaluated in multiple myeloma.
| SparkCures ID | 382 |
|---|---|
| Developed By | Active Biotech AB |
| Generic Name | Tasquinimod |
| Additional Names | ABR-215050, CID 54682876 |
| Treatment Classifications |
|
View all active clinical trials around the US.
The following is a listing of clinical trials for patients with multiple myeloma who have received one to two prior lines of therapy.
The following is a listing of clinical trials for patients with multiple myeloma who have received three or more prior lines of therapy.